DexCom Inc. (DXCM) Shares Bought by BNP Paribas Arbitrage SA
BNP Paribas Arbitrage SA increased its stake in DexCom Inc. (NASDAQ:DXCM) by 3,320.0% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 1,197 shares of the medical device company’s stock after buying an additional 1,162 shares during the period. BNP Paribas Arbitrage SA’s holdings in DexCom were worth $105,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in DXCM. Loomis Sayles & Co. L P raised its position in DexCom by 0.4% in the first quarter. Loomis Sayles & Co. L P now owns 25,898 shares of the medical device company’s stock valued at $1,759,000 after buying an additional 94 shares during the last quarter. Nicholas Investment Partners LP raised its position in DexCom by 2.4% in the first quarter. Nicholas Investment Partners LP now owns 78,762 shares of the medical device company’s stock valued at $5,349,000 after buying an additional 1,849 shares during the last quarter. Riverhead Capital Management LLC acquired a new position in DexCom during the first quarter valued at approximately $3,951,000. AXA raised its position in DexCom by 2.5% in the first quarter. AXA now owns 524,721 shares of the medical device company’s stock valued at $35,634,000 after buying an additional 12,791 shares during the last quarter. Finally, State Street Corp raised its position in DexCom by 7.2% in the first quarter. State Street Corp now owns 1,055,774 shares of the medical device company’s stock valued at $71,699,000 after buying an additional 71,009 shares during the last quarter. 99.37% of the stock is currently owned by institutional investors and hedge funds.
DexCom Inc. (NASDAQ:DXCM) opened at 81.68 on Friday. DexCom Inc. has a one year low of $47.92 and a one year high of $96.38. The stock’s 50 day moving average is $89.65 and its 200 day moving average is $78.55. The firm’s market cap is $6.85 billion.
DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.12. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The company earned $137.30 million during the quarter, compared to analyst estimates of $132.48 million. During the same quarter last year, the firm posted ($0.05) earnings per share. The firm’s revenue for the quarter was up 47.3% compared to the same quarter last year. On average, equities research analysts expect that DexCom Inc. will post ($0.57) earnings per share for the current year.
DXCM has been the topic of several research reports. JPMorgan Chase & Co. restated a “buy” rating on shares of DexCom in a report on Monday, June 20th. Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “sell” rating in a report on Tuesday, June 28th. Canaccord Genuity restated a “buy” rating and issued a $95.00 price target on shares of DexCom in a report on Wednesday, July 13th. Jefferies Group reiterated a “buy” rating and set a $98.00 price objective (up previously from $90.00) on shares of DexCom in a research note on Friday, July 15th. Finally, Deutsche Bank AG lifted their price objective on shares of DexCom from $90.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, July 15th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $95.40.
In other news, CEO Kevin R. Sayer sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $90.98, for a total transaction of $1,819,600.00. Following the completion of the transaction, the chief executive officer now directly owns 362,227 shares in the company, valued at $32,955,412.46. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider John Lister sold 3,560 shares of the company’s stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $84.41, for a total value of $300,499.60. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.